Janone advances toward initiation of phase 2b peripheral artery disease (pad) trial for lead product candidate jan101

Las vegas, june 8, 2021 /prnewswire/ -- janone inc. (nasdaq: jan), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the successful completion of current good manufacturing practices (cgmp) production of the first batch of jan101 for its upcoming phase 2b trial for treating peripheral artery disease (pad). the initial batch, produced by manufacturing partner corerx, contains approximately 200,000 sustained release tablets and matching placebos of jan101, a patented sustained-release form of sodium nitrite aimed at improving vascular function and reducing neuropathic pain and other conditions resulting from poor blood flow.
JAN Ratings Summary
JAN Quant Ranking